Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Prati

Showing results (11-20 of 11) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 11 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Pageof 2

Showing results (11-20 of 11) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 11 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)Rodolfo Passalacqua, Caterina Caminiti, Sebastiano Buti, et al.
Pageof 2